139 related articles for article (PubMed ID: 12822405)
21. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
22. Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy.
Kalayoglu-Besisik S; Ozturk GB; Caliskan Y; Nalcaci M; Gurses N; Cin N; Ozbek U; Sargin D
Transfus Apher Sci; 2007 Feb; 36(1):91-4. PubMed ID: 17222585
[TBL] [Abstract][Full Text] [Related]
23. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
24. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
25. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
26. Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.
Simon W; Segel GB; Lichtman MA
Blood Cells Mol Dis; 2006; 37(2):116-24; discussion 125-7. PubMed ID: 16904348
[TBL] [Abstract][Full Text] [Related]
27. Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex.
Rowe JM; Rapoport AP; Ryan DH; Nilsson BI; Duerst RE; Packman CH; Abboud CN; DiPersio JF; Linder T; Wang N; Simonsson B; Liesveld JL
Bone Marrow Transplant; 1999 Nov; 24(10):1057-63. PubMed ID: 10578155
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
[TBL] [Abstract][Full Text] [Related]
29. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
[TBL] [Abstract][Full Text] [Related]
30. t(3;21) following peripheral blood stem cell transplantation in chronic phase chronic myeloid leukaemia.
Jacob A; Griffiths M; Larkins S; Holmes J
Bone Marrow Transplant; 1997 Jun; 19(12):1255-8. PubMed ID: 9208122
[TBL] [Abstract][Full Text] [Related]
31. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
Salesi N; Bossone G; Della Longa G; Di Cocco B
Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia].
Sugawara W; Endo M; Nakatuji Y; Hosokawa T; Chida S
Rinsho Ketsueki; 2003 Sep; 44(9):962-4. PubMed ID: 14577318
[TBL] [Abstract][Full Text] [Related]
33. Autografting in chronic myeloid leukemia.
Carella AM; Beltrami G; Corsetti MT
Semin Hematol; 2003 Jan; 40(1):72-8. PubMed ID: 12563613
[TBL] [Abstract][Full Text] [Related]
34. Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
Avery S; Nadal E; Marin D; Olavarria E; Kaeda J; Vulliamy T; Brito Babapulle F; Goldman JM; Apperley JF
Leuk Res; 2004 May; 28 Suppl 1():S75-7. PubMed ID: 15036946
[TBL] [Abstract][Full Text] [Related]
35. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
36. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
37. Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Moser AM; Manor E; Narkis G; Kapelushnik J
Cancer Genet Cytogenet; 2006 Oct; 170(1):54-7. PubMed ID: 16965955
[TBL] [Abstract][Full Text] [Related]
38. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Weisser M; Tischer J; Schnittger S; Schoch C; Ledderose G; Kolb HJ
Haematologica; 2006 May; 91(5):663-6. PubMed ID: 16627251
[TBL] [Abstract][Full Text] [Related]
39. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
Kolb EA; Pan Q; Ladanyi M; Steinherz PG
Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
[TBL] [Abstract][Full Text] [Related]
40. Selective overshoot of Ph-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion.
Carella AM; Podestà M; Frassoni F; Pungolino E; Pollicardo N; Raffo MR; Ferrero R; Benvenuto F; Figari O; Giordano D
Stem Cells; 1993 Oct; 11 Suppl 3():67-72. PubMed ID: 7905325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
